On Wednesday, TiVo Inc. (NASDAQ:TIVO)’s shares declined -0.44% to $9.06.
TiVo Inc. ( TIVO), a leading innovator in the advanced television space, recently declared that President and CEO Tom Rogers will present at Goldman Sachs’ 24th Annual Communacopia Conference on Wednesday, September 16th. A webcast of the presentation will be accessible on the Investor Relations section of the TiVo website at http://investor.tivo.com under the events calendar tab.
Conference Details:
Goldman Sachs’ 24th Annual Communacopia Conference
New York, NY
Wednesday, September 16, 2015
1:15 p.m. ET
Tom Rogers, President and CEO
TiVo Inc. provides television software services and cloud-based software-as-a-service solutions that enable to view video content through various screens. It offers whole-home solutions that comprise 4-Tuner and 6-Tuner digital video recorders (DVRs)/gateways, non-DVR IP set-top boxes (STBs), and software to enable streaming to application on third-party devices, such as iOS and Android mobile phones and tablets through features, such as What to Watch Now, OnePass, integrated search, access to broadband video content, and TiVo online/mobile scheduling.
Palo Alto Networks Inc (NYSE:PANW)’s shares dropped -0.79% to $165.15.
Palo Alto Netoperates (PANW), the next-generation security company, recently declared financial results for its fiscal fourth quarter and fiscal year ended July 31, 2015.
Total revenue for the fiscal fourth quarter 2015 grew 59 percent year-over-year to a record $283.9 million, contrast with total revenue of $178.2 million for the fiscal fourth quarter 2014. GAAP net loss for the fiscal fourth quarter 2015 was $46.0 million, or $0.55 per diluted share, contrast with GAAP net loss of $32.1 million, or $0.41 per diluted share, for the fiscal fourth quarter 2014.
Non-GAAP net income for the fiscal fourth quarter 2015 was $25.0 million, or $0.28 per diluted share, contrast with non-GAAP net income of $9.1 million, or $0.11 per diluted share, for the fiscal fourth quarter 2014. A reconciliation between GAAP and non-GAAP information is contained in the tables below.
Palo Alto Netoperates, Inc. provides enterprise security platform to enterprises, service providers, and government entities worldwide. Its platform comprises Next-Generation Firewall that delivers application, user, and content visibility and control, in addition to protection against network-based cyber threats; and Threat Intelligence Cloud that offers central intelligence capabilities, in addition to automated delivery of preventative measures against cyber attacks.
At the end of Wednesday’s trade, Mattel, Inc. (NASDAQ:MAT)‘s shares dipped -0.83% to $22.81.
American Girl is a premium brand for girls and a wholly owned partner of Mattel, Inc. (MAT) (www.mattel.com). American Girl has partnered again with pediatrician and New York Times bestselling author, Dr. Cara Natterson, on a new go-to guide for moms and daughters. The new three-book set, The Care & Keeping of Us: A Sharing Collection for Girls and Their Moms, provides the tools to get the conversation going on topics most top-of-mind for growing girls—from body basics, hygiene, and healthy habits to friends, social media, clothing, and more. The new advice series is a follow-up to Natterson’s 2013 American Girl bestseller The Care & Keeping of You 2: The Body Book for Older Girls, which has sold over 400,000 copies to date.
Mattel, Inc. designs, manufactures, and markets a range of toy products worldwide. The company operates in three segments: North America, International, and American Girl. It offers dolls and accessories, vehicles and play sets, and games and puzzles under the Mattel Girls & Boys brands, counting Barbie, Monster High, Disney Classics, Ever After High, Little Mommy, Polly Pocket, Hot Wheels, Matchbox, CARS, Disney Planes, BOOMco, Radica, Toy Story, Max Steel, WWE Wrestling, and Batman. The company also provides its products under the Fisher-Price brands, such as Fisher-Price, Little People, BabyGear, Laugh & Learn, Imaginext, Thomas & Friends, Dora the Explorer, Mickey Mouse Clubhouse, Disney Jake, the Never Land Pirates, and Power Wheels.
Cytori Therapeutics Inc (NASDAQ:CYTX), ended its Wednesday’s trading session with 7.63% gain, and closed at $0.409.
Cytori Therapeutics (CYTX) declared the publication of the results from the 12 month clinical follow up of patients enrolled in the Scleradec-I clinical trial from hand dysfunction common in patients with the rare disease scleroderma. The Scleradec-I trial, an investigator-initiated, open-label 12 patient trial, was led by Dr. Brigitte Granel and Dr. Guy Magalon from the Assistance Publique des Hôpitaux de Marseille. The manuscript was published in the journal Rheumatology [http://rheumatology.oxfordjournals.org/content/early/2015/09/08/rheumatology.kev323.abstract].
The publication documented that a single treatment with Cytori Cell Therapy™, known as ECCS-50, offered prolonged improvements in patients with impaired hand function due to scleroderma. Specifically, hand function assessed using the validated clinical measure known as the Cochin Hand Function Scale and overall health status using the Scleroderma Health Activity Questionnaire improved from baseline by an average of 51.3% and 46.8%, respectively, at 12 months (p≤0.001 for both). Raynaud’s Condition Score, which measures the incidence and severity of Raynaud’s phenomena, was reduced by 63.2% from baseline at 12 months (p<0.001). Other key findings comprise a 30.5% improvement from baseline in grip strength (p=0.002) and 34.5% improvement from baseline in pain (p=0.052).
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy compriseing of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
